Search
Candesartan cilexetil
go.drugbank.com/drugs/DB00796ApprovedInvestigationalCandesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents … Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension.
Mixtures: CO-UCAND 16/12.5 MG FILM TABLET, 84 ADET, CO-UCAND 32/12.5 MG FILM TABLET, 84 ADETMirvetuximab soravtansine
go.drugbank.com/drugs/DB12489ApprovedInvestigational[A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1. … Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide
Sirolimus
go.drugbank.com/drugs/DB00877ApprovedInvestigational[A242372] In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. … rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to
Colfosceril palmitate
go.drugbank.com/drugs/DB09114ApprovedWithdrawn[T70] It was developed by Burroughs Wellcome and it was FDA approved on August 6, 1990.[L1109] Nowadays colfosceril palmitate is under the state of canceled post-marketing.
Estradiol valerate
go.drugbank.com/drugs/DB13956ApprovedInvestigationalVet approvedHowever, after menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. … First-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter systemic circulation and exert its estrogenic effects [A12102].
Lonapegsomatropin
go.drugbank.com/drugs/DB16220ApprovedInvestigational[L36380] It was later approved by the European Commission on 13 January 2022.[L39900] … TransCon hGH or ACP 001, is a methoxypegylated prodrug of human growth hormone ([somatropin]) indicated for the treatment of children 1 year and older, weighing at least 11.5 kg, with growth failure due to
Insulin lispro
go.drugbank.com/drugs/DB00046ApprovedInvestigationalInsulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose … in position B29 is replaced by proline.
Suzetrigine
go.drugbank.com/drugs/DB18927ApprovedInvestigational[A264953] On January 30, 2025, suzetrigine was approved by the FDA as a first-in-class non-opioid analgesic.[L52098] … Suzetrigine is a Na<sub>V</sub>1.8 voltage-gated sodium channel blocker with analgesic properties[A264948] Na<sub>V</sub>1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain
Fondaparinux
go.drugbank.com/drugs/DB00569ApprovedInvestigationalOnce bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. … Fondaparinux may be used: to prevent venous thromboembolism in patients who have undergone orthopedic surgery of the lower limbs (e.g. hip fracture, hip replacement and knee surgery); to prevent VTE in
Gadoteridol
go.drugbank.com/drugs/DB00597ApprovedInvestigational[A263076,A263081,L49871] It was 1 of the 3 macrocyclic gadolinium-based contrast agents (GBCAs) that was mandated by the EMA to replace linear gadolinium-based contrast agents due to concerns about retained … [A263076] Initially approved by the FDA in 1992, gadoteridol received additional approval in 2020 for use in pediatric patients less than 2 years old.[L49876]
Synonyms: GD-HP-DO 3A